drugset / Trial / NCT02735707

Summary

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Timeline

Start
2016-04-11
Primary completion
2026-02
Completion
2028-02

Outcome

Mixed primary results

paper Both tocilizumab and sarilumab met the predefined criteria for efficacy. PMID 33631065 ↗

paper Although recruitment was stopped because cases had decreased, among critically ill patients with Covid-19, simvastatin did not meet the prespecified criteria for superiority to control. PMID 37888913 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin-clavulanate Other / unclassified — —
Subject Anakinra Protein / enzyme biologic 100 mg Intravenous
Subject Apremilast Small molecule 30 mg —
Subject Aspirin Small molecule 75 mg —
Subject Aspirin Small molecule 100 mg —
Subject Azithromycin Small molecule — Intravenous
Subject Baloxavir Marboxil Unknown — —
Subject Baricitinib Small molecule — —
Subject Candesartan Unknown — —
Subject Captopril Small molecule — —
Subject Ceftaroline Other / unclassified — —
Subject Ceftriaxone Other / unclassified — —
Subject Clarithromycin Small molecule — Intravenous
Subject Clopidogrel Small molecule 75 mg —
Subject Convalescent Plasma Protein / enzyme biologic — —
Subject Cysteamine Unknown 5 mg/kg —
Subject DMX-200 Unknown 120 mg Oral
Subject Dexamethasone Small molecule 6 mg Intravenous
Subject Enalapril Other / unclassified — —
Subject Eritoran Small molecule 6.56 mg Intravenous
Subject Heparin Other / unclassified — —
Subject Hydrocortisone Other / unclassified 50 mg Intravenous
Subject Hydrocortisone Other / unclassified 100 mg Intravenous
Subject Hydroxychloroquine Small molecule 400 mg Oral
Subject Imatinib Small molecule 400 mg Oral
Subject Interferon beta-1a Protein / enzyme biologic 10 ug Intravenous
Subject Irbesartan Small molecule — —
Subject Ivermectin Small molecule 0.2 mg/kg Oral
Subject LISINOPRIL ANHYDROUS Small molecule — —
Subject Levofloxacin Small molecule — —
Subject Lopinavir Other / unclassified 400 mg —
Subject Losartan Other / unclassified — —
Subject Moxifloxacin Small molecule — —
Subject Nirmatrelvir Small molecule — —
Subject Olmesartan Other / unclassified — —
Subject Oseltamivir Small molecule — —
Subject Perindopril Small molecule — —
Subject Piperacillin-tazobactam Unknown — —
Subject Prasugrel Small molecule 10 mg —
Subject Ramipril Small molecule — —
Subject Remdesivir Small molecule 100 mg —
Subject Ritonavir Other / unclassified 100 mg —
Subject Ritonavir Other / unclassified — —
Subject Sarilumab Monoclonal antibody 400 mg Intravenous
Subject Simvastatin Small molecule 80 mg Oral
Subject Telmisartan Other / unclassified — —
Subject Ticagrelor Small molecule 60 mg —
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous
Subject Valsartan Unknown — —
Subject Vitamin C Other / unclassified 50 mg/kg Intravenous
Subject roxithromycin Small molecule — —
Subject trandolapril Small molecule — —

Indications